Other · developed by Fresenius Kabi Usa
SMOFlipid is a lipid emulsion for intravenous infusion, containing soybean oil, MCT, olive oil and fish oil. It supplies calories and essential fatty acids, which are used for energy through beta oxidation and serve as membrane components and precursors of bioactive molecules. It is studied in malnutrition, essential fatty acid deficiency and parenteral nutrition associated cholestasis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 15, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06049680 | Phase 4 | Malnutrition, Child | Recruiting | FMS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Essential Fatty Acid Deficiency (EFAD)MalnutritionMalnutrition, ChildParenteral Nutrition Associated Cholestasis
Updated Nov 8, 2026. Something wrong or missing? Report it on the FMS page.
See FMS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FMS catalysts and pipeline →